AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN) announced today its financial results for the quarter and year ended December 31, 2007, and provided guidance regarding its operations including its planned pivotal clinical trial data presentations and regulatory submissions schedule.
